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INTRODUCTION
Very long chain acyl-CoA dehydrogenase deficiency (VLCADD, MIM 201475) is
an autosomal recessive disorder characterized by impaired mitochondrial β-
oxidation of fatty acids with a chain length between 14 and 18 carbons. The
prevalence of VLCAD deficiency in Portugal is 1/101,613. VLCADD has three
forms of clinical presentation: severe early-onset; intermediate with childhood
onset and adult-onset, of mild severity, characterized by exercise intolerance,
myalgia and recurrent episodes of rhabdomyolysis (1). The VLCAD gene
(ACADVL) contains 20 exons that encode a 655-amino-acid protein and it is
located on chromosome 17p13. More than 116 mutations have been identified
in the literature (HGMD).
The development of electrospray ionization tandem mass spectrometry
(MS/MS) has allowed beyond the screening of neonatal forms a marked
improvement on diagnosis of the adult onset form, through the analysis of
acylcarnitine profiles from blood spots, using C14:1 as primary marker. The
molecular study of ACADVL gene allowed the confirmation of the patients.
Table 1- Clinical classification of the seven VLCADD patients. Family A-patients 1 and 2 
are brothers; Family C-patients 4 and 5 are brothers.
 Family A Family B Family C Family D Family E 
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 
Age/sex 13 Years 
Female 
19 Years  
Male 
51 Years  
Male 
11 Years 
Male 
20 Years 
Male 
14 Years 
 Female 
63 Years 
Female 
Clinical 
phenotype 
-Severe 
generalized 
muscle pain  
-Dark urine after 
prolonged  
physical effort 
-CPK↑ 
-mioglobin↑ 
-mioglubinuria  
-Episodes of 
muscle pain 
-Dark urine 
after physical 
effort  of 
moderate 
intensity since 
the age 17 
-At  age 18 
hospitalization 
due to not 
elucidated 
rhabdomyolysis 
 
- Experienced the 
first of several 
recurrent 
episodes of 
myalgia at 20 
years 
-Muscle 
weakness 
-Rhabdomyolysis 
following 
prolonged 
exercice 
-CPK↑ 
-Exercise 
intolerance  
-Dark urine  
-Myalgia 
-Rhabdomyolysis  
- Rhabdomyolysis -Rhabdomyolysis  
-Myalgia  
 
PATIENTS AND METHODS 
The authors report seven individuals from five
families with clinical symptoms and ages between 11
y-63y (Table 1). Blood spot samples are collected in
Whatman 903 filter paper.
Acylcarnitines were analysed as butyl esters on an
API 2000 triple quadrupole tandem mass
spectrometer (AppliedBiosystems, Sciex) with an ion
spray device, as previously described with minor
modifications (2).
Genomic DNA was extracted from blood of patients
and their parents by standard methods. All 20 exons
of the ACADVL gene (3), and respective flanking
regions, were amplified by PCR, using newly
designed primers and was performed on an
automatic sequencer (ABI Prism 3130XL).
Table 2- Biochemical and molecular data from the seven VLCADD patients.
DISCUSSION / CONCLUSION
In spite of the heterogeneity of genotype usually associated with VLCADD, in these cases we found the same mutation (p.L500del) in 10/14 allels and
another mutation p.R366H in 3/4 reaming allels. This fact may indicate that this mutations are commonly associated with mild VLCADD form in the
Portuguese population.
When rhabdomyolysis is present in a patient, and after differential diagnosis exclusion, it is important to consider the possibility of a VLCAD
deficiency.
However late-onset forms may be undetectable by acylcarnitine profile in asymptomatic period, and whenever possible samples should be taken in in
crisis period. If VLCADD is considered suspicious the molecular analysis of ACADVL should be performed even in the presence of a normal
acilcarnitines profile , to avoid a late diagnosis.
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RESULTS
The analysis by tandem mass spectrometry of the acylcarnitines profile in seven
individuals with clinical symptoms revealed accumulation of tetradecenoyl carnitine
(C14:1), suggesting the diagnosis of VLCADD. The molecular characterization allowed the
identification of mutations in all cases (Table 2), thus confirming this diagnosis.
 C14:1 
µM 
C14:2 
µM 
C14:1/C16 C14:1/C12:1  
                             Genotype                                            Deduced effect 
Ref. value <0.18 <0.08 <0.19 <2.60 
Patient 1 0.35 0.23 0.30 4.38 c.[1500 _1502delCCT]+ [1500 _1502delCCT] p.[L500del]+[L500del] 
Patient 2 0.25 0.01 0.10 1.25 c.[1500 _1502delCCT]+ [1500 _1502delCCT] p.[L500del]+[L500del] 
Patient 3 7.17 0.67 2.43 15.42 c.[1097G>A]+[1097G>A] p.[R366H]+[R366H] 
Patient 4 0.47 0.17 0.46 5.88 c.[1500 _1502delCCT]+ [1500 _1502delCCT] p.[L500del]+[L500del] 
Patient 5 0.22 0.10 0.16 1.70 c.[1500 _1502delCCT]+ [1500 _1502delCCT] p.[L500del]+[L500del] 
Patient 6 1.27 0.30 1.72 9.77 c.[187_192insA]+[1097G>A] p.[P65Tfs*7]+[R366H] 
Patient 7 0.25 0.09 0.52 3.64 c.[1500 _1502delCCT]+ [1500 _1502delCCT] p.[L500del]+[L500del] 
 
